Skip to main content
. Author manuscript; available in PMC: 2017 Jul 14.
Published in final edited form as: J Dermatol Sci. 2016 Dec 12;85(3):197–207. doi: 10.1016/j.jdermsci.2016.12.010

Fig. 3.

Fig. 3

Desmoglein 1 (Dsg1) clustering needed not only a pathogenic anti-Dsg1 antibody, but also cross-linking of Dsg1 molecules by a non-pathogenic anti-Dsg1 IgG antibody. Immunofluorescence of Dsg1 staining of human skin injection assay is captured by confocal microscope. Schema show comparing the effect between IgG and single-chain variable fragment (scFv) form of anti-Dsg1 monoclonal antibodies (mAbs). A: The mixture injection of PF1-8-15 IgG and PF1-2-6 IgG (PF1-8-15 IgG + PF1-2-6 IgG) caused Dsg1 clustering and blistering. PF1-8-15 IgG disturbed trans-interaction of Dsg1 molecules. PF1-2-6 IgG caused cross-linking of Dsg1 molecules. B: The mixture injection of PF1-8-15 scFv and PF1-2-6 scFv (PF1-8-15 scFv + PF1-2-6 scFv) did not cause Dsg1 clustering, but caused blistering. ScFv type antibodies could not cause cross-linking of Dsg1 molecules because they had only one antigen binding site. C: The mixture injection of PF1-8-15 IgG and PF1-2-6 scFv (PF1-8-15 IgG + PF1-2-6 scFv) did not cause Dsg1 clustering, but caused blisteing. PF1-8-15 IgG disturbed trans-interaction of Dsg1 molecules, but did not cause cross-linking of Dsg1 molecules. D: The mixture injection of PF1-8-15 scFv and PF1-2-6 IgG (PF1-8-15 scFv + PF1-2-6 IgG) caused Dsg1 clustering and blistering. PF1-2-6 IgG caused cross-linking of Dsg1 molecules. E: The mixture injection of two different non-pathogenic anti-Dsg1 IgG mAbs (PF1-2-6 IgG + PF1-2-22 IgG) did not cause Dsg1 clustering and blistering. Bar = 20 μm.